Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2, Merck & Co., Inc. ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Merck & Co. said the U.S. Food and Drug Administration will review its application seeking approval of its proposed doravirine/islatravir regimen in certain adults with HIV-1 infection. Merck on ...